Fresenius-licensed Endexo Smart Polymer Gets FDA Breakthrough Status to Prevent Clots
nterface Biologics Inc. (IBI) from Canada has developed Endexo as a way to help make dialyzer membranes and bloodlines more biocompatible—and less likely to clot. The technology, for which Fresenius holds an exclusive world-wide license, will reduce the need for heparin and other blood thinners.
Read the full article » | Posted 11-16-2019
Related Articles
- New Measure of Home Dialysis Dropout Posted 01-16-2024
- Check out the NextKidney Neokidney HD Machine Posted 11-15-2023
- New Redsense Clamp Add-on Will Stop the Blood Pump! Posted 10-13-2023
- AWAK Technologies Raised Another $20 million for Shoulder Bag Sized Wearable PD Posted 10-13-2023